 |
|
|
| |
NAFLD IS COMMON AND ASSOCIATED WITH
CARDIOVASCULAR RISK IN REPRIEVE PARTICIPANTS
|
| |
| |
CROI 2022 Feb 11-16
Carl J. Fichtenbaum, MD1 Heather J. Ribaudo, PhD2 , Jana Taron, MD3, Jorge Leon-Cruz, MS2, Netanya S. Utay, MD4 Ken S. Ho, MD, MSc5, Anne F. Luetkemeyer, MD6, Shobha Swaminathan, MD7, Carrie D. Johnston, MD, MSc8, Evelynne S. Fulda, BA9, Emma Kileel, MPH9, Michael T. Lu, MD, MPH10, Steven K. Grinspoon, MD9, Jordan E. Lake, MD11, and REPRIEVE Trial Investigators. 1University of Cincinnati, 2Harvard T.H. Chan School of Public Health, 3University Medical Center Freiburg, 4University of Texas Southwestern Medical Center, 5University of Pittsburgh School of Medicine, 6University of California, San Francisco, 7Rutgers New Jersey Medical School, 8Weil Cornell School of Medicine, 9Massachusetts General Hospital, 10 Harvard Medical School, 11University of Texas Health Science Center.
|
| |
|
|
|
|
|
